IndustryCompany release
Omeros Q3 sales of Yartemlea rise 26% as CHMP upholds negative opinion on narsoplimab
🇺🇸 Omeros Corp (OMER) · Mon 16 Nov 2026
Omeros reported $35.9M in net revenue for its stem cell transplant TMA drug, while the EMA's CHMP kept its negative opinion on the EU application after re-examination.
Omeros Corp reported third-quarter 2026 results on 16 November, citing net revenue of $35.9M for Yartemlea (narsoplimab-wuug), up 26%. The product is approved in the US for transplant-associated thrombotic microangiopathy (TMA) following stem cell transplantation.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on VigiEye and CompePharma
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Company's press release (SEC filing): Omeros Corp ↗
Article written by VigiEye from the official source (Omeros Corp). Claims are the company's own. AI-assisted; check the source before acting.
More Industry
All →
Gedeon Richter to acquire Mayne Pharma in AUD 604 million cash deal
Gedeon Richter · Mon 16 Nov 2026
Metagenomi puts hemophilia A editing candidate MGX-001 first in November 2026 deck
🇺🇸 Metagenomi Therapeutics, Inc. (MGX) · Mon 16 Nov 2026
Lifeloc Q3 revenue rises 12% as SpinDetect drug analyzer launch slips to Q4 2027
🇺🇸 Lifeloc Technologies, Inc (LCTC) · Mon 16 Nov 2026
Aytu BioPharma to be acquired by Rosemont for about $56M as EXXUA sales grow
🇺🇸 Aytu Biopharma, Inc (AYTU) · Mon 16 Nov 2026
Merck KGaA to acquire Rapid Micro Biosystems in $0.75-per-share cash tender offer
🇺🇸 Rapid Micro Biosystems, Inc. (RPID) · Mon 16 Nov 2026
Glass House Brands more than doubles Q3 revenue to $56.8M as net loss narrows
Glass House Brands Inc. (GLAS) · Mon 16 Nov 2026